Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Mallinckrodt
Cerilliant
US Department of Justice
Dow
Harvard Business School
Express Scripts
Queensland Health
Medtronic
Federal Trade Commission

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,465,462

« Back to Dashboard

Which drugs does patent 7,465,462 protect, and when does it expire?


Patent 7,465,462 protects LUVOX CR and is included in one NDA. There have been two Paragraph IV challenges on Luvox CR.

This patent has twenty-two patent family members in eighteen countries.

Summary for Patent: 7,465,462

Title:Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
Abstract:A multiparticulate controlled release selective serotonin reuptate inhibitor (SSRI) formulation for oral administration is provided. The formulation includes particles of an SSRI or a pharmaceutically acceptable salt thereof, which are coated with a rate-controlling polymer that allows controlled release of the SSRI over a period of not less than about 12 hours after oral administration. The rate controlling polymer includes a film-forming water-insoluble polymer, or a mixture of a film-forming water-insoluble polymer and a film-forming water-soluble polymer.
Inventor(s): Jeary; Theresa Ann (Roscommon, IE), Morrissey; Catherine Ann (County Westmeath, IE), Stark; Paul (County Westmeath, IE)
Assignee: Elan Pharma International Limited (Monksland Athlone County Westmeath, IL)
Application Number:09/744,169
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Jazz Pharms
LUVOX CR
fluvoxamine maleate
CAPSULE, EXTENDED RELEASE;ORAL022033-001Feb 28, 2008DISCNYesNo► Subscribe► SubscribeY TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
Jazz Pharms
LUVOX CR
fluvoxamine maleate
CAPSULE, EXTENDED RELEASE;ORAL022033-002Feb 28, 2008DISCNYesNo► Subscribe► SubscribeY TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,465,462

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Ireland990406May 20, 1999
PCT Information
PCT FiledMay 10, 2000PCT Application Number:PCT/IE00/00060
PCT Publication Date:November 30, 2000PCT Publication Number: WO00/71099

International Patent Family for Patent: 7,465,462

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria367153► Subscribe
Australia4426700► Subscribe
Australia782059► Subscribe
Canada2374039► Subscribe
Canada2698347► Subscribe
Cyprus1107750► Subscribe
Czech Republic20014618► Subscribe
Czech Republic302388► Subscribe
Germany60035579► Subscribe
Denmark1178780► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Novartis
Dow
US Army
Boehringer Ingelheim
Colorcon
Deloitte
UBS
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot